Anti-CGRP monoclonal antibodies: focus on safety


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Migraine is a common socially significant disease, which until recently had no specific preventive therapy. The advent of monoclonal antibodies to the calcitonin-gene related peptide (CGRP) system has introduced a new era in the treatment of migraine. Since CGRP is a powerful vasodilator, cardiac safety of drugs that block this peptide has been studied especially carefully. There was no evidence of a negative effect of CGRP blockers on hemodynamic parameters and the severity of ischemia in arterial occlusion. In the study with the monitoring of 1287patients with cardiovascular diseases or their risk factors (diabetes mellitus, arterial hypertension, obesity, etc.), no negative effects of fremanizumab on the cardiovascular system, including blood pressure and electrocardiography parameters, were detected. According to a stress test, it was shown that intravenous administration of erenumab at a dose of 140 mg does not affect the exercise tolerance and the development of myocardial ischemia. Anti-CGRP monoclonal antibodies have high efficacy and safety.

Full Text

Restricted Access

About the authors

Ya. I Ashikhmin

University Headache Clinic

Email: ya.ashikhmin@gmail.com
PhD, Cardiologist, Advisor to the Director General of the International Medical Cluster Foundation

Yu. E Azimova

University Headache Clinic; Research Institute of General Pathology and Pathophysiology

References

  1. Ayzenberg і., Katsarava Z., Sborowski A., et a. The prevalence of primary headache disorders in Russia: a countrywide survey. Cephalalgia. 2012;32(5):373-81. doi: 10.1177/0333102412438977.
  2. Russell FA., King R., Smillie S.J., et al. Calcitonin gene-related peptide: physiology and pathophysiology. Physiol Rev. 2014;94:1099-42. Doi: 10.1152/ physrev.00034.2013.
  3. Raffael B, Israel H., Neeb L., et al. The safety and efficacy of the 5-HT 1 F receptor agonist lasmiditan in the acute treatment of migraine. Expert Opin Pharmacother. 2017;18:1409-15.
  4. Kim Y.G., Lone A.M., Saghatelian A. Analysis of the proteolysis of bioactive peptides using a peptidomics approach. Nat Protoc. 2013;8:1730-42. doi: 10.1038/nprot.2013.104.
  5. McLatchie L.M., Fraser N.J., Main M.J., et al. RAMPs regulate the transport and ligand specificity of the calcitonin- receptor-like receptor. Nature. 1998;393:333-39.
  6. Edvinsson L., Fredholm B.B., Hamel E, et al. Perivascular peptides relax cerebral arteries concomitant with stimulation of cyclic adenosine monophosphate accumulation or release of an endothelium- derived relaxing factor in the cat. Neurosci Lett. 1985;58:213-17.
  7. Hansen J.M., Hauge A.W., Olesen J., Ashina M. Calcitonin generelated peptide triggers migrainelike attacks in patients with migraine with aura. Cephalalgia. 2010;30:1179-86. doi: 10.1177/0333102410368444.
  8. Bell i.M. Calcitonin gene- related peptide receptor antagonists: new therapeutic agents for migraine. J. Med. Chem. 2014;57:7838-58. Doi: 10.1021/ jm500364u.
  9. Shi L., Lehto S.G., Zhu D.X., et al. Pharmacologic characterization of AMG 334, a potent and selective human monoclonal antibody against the calcitonin generelated peptide receptor. J Pharmacol Exp Ther 2016;356:223-31. Doi: 10.1124/ jpet.115.227793.
  10. Monteith D, Collins E.C., Vandermeulen C., et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of the CGRP binding monoclonal antibody LY2951742 (Galcanezumab) in healthy volunteers. Front Pharmacol. 2017;8:740. doi: 10.3389/fphar.2017.00740.
  11. URL: https://globenewswire.com/news-release/2018/01/08/1284947/0/en/Alder-Announces-Eptinezumab-Significantly-Reduces-Migraine-Risk-Meets-Primary-and-All-Key-Secondary-Endpoints-in-Pivotal-PROMISE-2-Phase-3-Trial-for-Chronic-Migraine-Prevention.html.
  12. Reuter U, Goadsby PJ., Lanteri-Minet M., et al. Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3bstudy. Lancet. 2018;392(10161):2280-87. doi: 10.1016/S0140-6736(18)32534-0.
  13. Martelletti P. The Application of CGRP(r) Monoclonal Antibodies in Migraine Spectrum: Needs and Priorities. BioDrugs. 2017;31(6):483-85. Doi: 10.1007/ s40259-017-0251-4.
  14. Sacco S., Bendtsen L., Ashina M., et al. European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention. J Headache Pain. 2019;20(1):6. Doi: 10.1186/ s10194-018-0955-y.
  15. Ashina M., et al. Efficacy of Erenumab (a fully human Mab targeting the CGRP receptor) in Chronic Migraine Patients with Prior Treatment Failure: a Subgroup Analysis of the Phase 2, Randomized, Double-Blind, Placebo-Controlled Study. Cephalalgia. 2017;37:326-27.
  16. Ritter L., Flower R., Henderson G., Rang H. Rang & Dale’s Pharmacology. 8th Edition, 2015.
  17. Mavridis T, Koniari C., Fakas N., Mitsikostas D. Anti-Calcitonin Gene-Related Peptide Monoclonal Antibodies: Adverse Effects. What Do We Really Know? Liter Rev EMJ Innov. 2019;3(1):64-72.
  18. Presta L. Engineering of therapeutic antibodies to minimize immunogenicity and optimize function. Adv Drug Deliv Rev. 2006);58:640-56.
  19. Deen M., Correnti E., Kamm K., et al. Blocking CGRP in migraine patients - a review of pros and cons. J Headache Pain. 2017;18:96. doi: 10.1186/s10194-017-0807-1.
  20. Peskar B.M., Wong H.C., Walsh J.H., Holzer P. A monoclonal antibody to calcitonin gene-related peptide abolishes capsaicin-induced gastroprotection. Eur J Pharmacol. 1993;250:201-3. doi: 10.1016/0014-2999(93)90645-X.
  21. Dodick D., Ashina M., Brandes J., et al. ARISE: A Phase 3 randomized trial of erenumab for episodic migraine. Cephalalgia. 2018;38(6):1026-37. doi: 10.1177/0333102418759786.
  22. Rubio-Beltran E., Maassen van den Brink A. Understanding CGRP and Cardiovascular Risk. Handbook of Experimental Pharmacology. Springer Nature Switzerland AG, 2019. doi: 10.1007/164_2019_204.
  23. Jianping L., Kevin A.C., Donald J.D., Scott C.S. Renal protective effects of a-calcitonin generelated peptide in deoxycorticosterone-salt hypertension. Am J Physiol Renal Physiol. 2013;304:1000-8. Doi: 10.1152/ ajprenal.00434.2012.
  24. Aubdool A.A., Thakore P, Argunhan F, et al. A novel alphacalcitonin gene-related peptide analogue protects against end-organ damage in experimental hypertension, cardiac hypertrophy, and heart failure. Circulation. 2017;136:367-83. Doi: 10.1161/ CIRCULATI0NAHA.117.028388.
  25. Liu Z., Liu Q., Cai H., et al. Calcitonin gene-related peptide prevents blood-brain barrier injury and brain edema induced by focal cerebral ischemia reperfusion. Regul Pept. 2011;171:19-25. Doi: 10.1016/j. regpep.2011.05.014.
  26. Juul R., Aakhus S., Bjornstad K., et al. Calcitonin gene-related peptide (human alpha-CGRP) counteracts vasoconstriction in human subarachnoid haemorrhage. Neurosci Lett. 1994;170(1):67-70.
  27. Xiao Z.S., Li Y.J., Deng H.W Ischemic preconditioning mediated by calcitonin gene-related peptide in isolated rat hearts. Zhongguo Yao Li Xue Bao. 1996;17(5):445-48.
  28. Gennari C., Nami R., Agnusdei D., Fischer J.A. Improved cardiac performance with human calcitonin gene related peptide in patients with congestive heart failure. Cardiovasc Res. 1990;24:239-41.
  29. Favoni V., Giani L., Al-Hassany L., et al. CGRP and migraine from a cardiovascular point of view: what do we expect from blocking CGRP? J Headache Pain. 2019;20:27. doi: 10.1186/s10194-019-0979-y.
  30. Bussiere J.L., Davies R., Dean C., et al. Nonclinical safety evaluation of erenumab, a CGRP receptor inhibitor for the prevention of migraine. Regul Toxicol Pharmacol. 2019;(106):224-38. Doi: 10.1016/j. yrtph.2019.05.013.
  31. Aviles-Rosas V.H., Rivera-Mancilla E., Marichal-Cancino B.A., et al. Olcegepant blocks neurogenic and non-neurogenic CGRPergic vasodepressor responses and facilitates noradrenergic vasopressor responses in pithed rats. Br J Pharmacol. 2017;174:2001-14. doi: 10.1111/bph.13799.
  32. Petersen K.A., Birk S., Lassen L.H., et al. The CGRP-antagonist, BIBN4096BS does not affect cerebral or systemic haemodynamics in healthy volunteers. Cephalalgia. 2005;25(2):139-47.
  33. Ning Х., Faulhaber Т., Lang N., et al. Fremanezumab Cardiovascular and Cerebrovascular Safety Profile: Pooled Data From Placebo-Controlled and Long-Term Studies. 2019;(15):92.
  34. Depre C., Antalik L., Starling A., et al. A randomized, double-blind, placebo-controlled study to evaluate the effect of Erenumab on exercise time during a treadmill test in patients with stable angina. Headache. 2018;58(5):715-23. doi: 10.1111/head.13316.
  35. Cui X., Ye J., Lin H., et al. Efficacy, safety, and tolerability of telcagepant in the treatment of acute migraine: a meta-analysis. Pain Pract. 2013;15(2):124-31. doi: 10.1111/papr.12158.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2019 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies